<DOC>
	<DOC>NCT00966095</DOC>
	<brief_summary>The purpose of this study is to develop and validate a blood-based diagnostic test that will predict prostate biopsy outcome as positive or negative for prostate cancer. Such a test will serve to reduce the number of unnecessary prostate biopsies.</brief_summary>
	<brief_title>PRostate Cancer Individual Signature Evaluation Trial in Patients Undergoing Scheduled Prostate Biopsy</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>. 1. Male over the age of 40. 2. Patient is scheduled for prostate biopsy for one or more of the following reasons: PSA &gt; 2.5 ng/ml Rising PSA (&gt;0.5 ng/ml/yr) Lower PSA value with other risk factors for prostate cancer (e.g.; family history) Abnormal DRE Percent free PSA &lt;15% 3. No prior history of prostate cancer or prostate biopsy. Unable or unwilling to provide informed consent</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>prostate cancer</keyword>
</DOC>